The short answer
Vitamin D supplements are not recommended with erdafitinib unless the cancer team specifically directs their use. A few hours of separation does not resolve the mineral-monitoring concern.
What this answer covers
Oral erdafitinib with vitamin D supplements. Mineral concentrations and phosphate-guided treatment decisions are distinct from a gut absorption interaction.
- Supplement or preparation
- Vitamin D
- Medication ingredient
- erdafitinib
Check the exact treatment
This review concerns oral erdafitinib tablets used for selected FGFR3-altered advanced bladder or urinary-tract cancers. Blood phosphate helps guide the initial dose decision, and monitoring continues during treatment. Supplements should be part of that individualized plan.
Why mineral levels matter
Vitamin D can contribute to increases in phosphate and calcium. The oral product information specifically discourages supplementation during erdafitinib treatment. This is not evidence that erdafitinib causes a vitamin D deficiency that should be corrected automatically.
The initial dose check has a special purpose
Blood phosphate is checked between days 14 and 21 to help the team decide whether to increase the starting dose. Products that raise or lower phosphate can interfere with that decision, so they are avoided during this initial period unless directed. Monitoring and management of high phosphate continue afterward.
Use an individualized supplement plan
Show the team all mineral products, antacids and vitamins. A documented low level may need treatment, but the team should choose the product and dose around current blood tests. Do not self-prescribe a binder, stop necessary nutrition or use a two-hour gap as a substitute for managing blood mineral levels.
Evidence and practical considerations
Timing & monitoring
Exact erdafitinib guidance supports a mineral-management precaution, not a universal chelation or numeric spacing rule.
- Exact scope
- Oral erdafitinib with vitamin D supplements. Mineral concentrations and phosphate-guided treatment decisions are distinct from a gut absorption interaction. with RxNorm 2123125 IN erdafitinib. Current exact oral product: BALVERSA oral erdafitinib tablets. Salt/formulation named explicitly; no transfer to unrelated drugs or routes.
- Medication form and route
- Oral
What remains uncertain
- Exact drug mineral guidance; Vitamin D supplementation warning is explicit in the inspected oral product information. Initial phosphate-altering restriction distinguished from continuing hyperphosphatemia management. No validated supplement spacing.
Factors that may matter: Exact oral formulation and supplement preparation; Drug exposure versus clinical outcomes; Dose, duration and other medicines; Individual monitoring plan.
Read the supporting source summaries
Source 1: Current original prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the exact oral formulation.
Phosphate elevations and soft-tissue mineralization; avoid phosphate-altering agents before initial titration and phosphate-increasing products thereafter; CYP3A/2C9 precautions.
How this applies: RxNorm 2123125 IN erdafitinib. Current exact oral product: BALVERSA oral erdafitinib tablets. Salt/formulation named explicitly; no transfer to unrelated drugs or routes.
Exact current oral product source, not a clinical trial of every supplement. Formulation, dose, population and mechanism remain explicit.
Source 2: Original cancer-center patient guidance
bccancer.bc.ca · Source check Sep 10, 2026
Population: Patients taking erdafitinib.
Avoid phosphate supplements; ask team before calcium/vitamin D to address mineral elevations.
How this applies: Exact medication supportive-care guidance.
Advice to review is not universal permanent prohibition or proven gut absorption interaction.
Source 3: Current original product information
medicines.org.uk · Source check Sep 10, 2026
Population: Adults prescribed oral erdafitinib.
Vitamin D supplementation not recommended because it may increase phosphate and calcium; non-calcium phosphate binder considered for persistent elevation.
How this applies: Exact drug mineral physiology.
Country-specific details differ from US label; no numeric supplement spacing or blanket calcium-food restriction.
Source 4: Medication terminology
rxnav.nlm.nih.gov · Source check Sep 10, 2026
Population: Terminology.
erdafitinib is IN.
How this applies: Exact ingredient.
Not clinical evidence.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Sources checked and article drafted. |
Article revision: eee8428984fa1641
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.